Rubeta Matin

Dr Matin is an academic dermatologist whose career began with an MRC Clinical Research Training Fellowship, leading to a PhD in Molecular Mechanisms in Melanoma (2010). Since then, she has established herself as a national expert and international leader in skin cancer and artificial intelligence (AI) research, with over 230 high-impact peer-reviewed publications (h-index 34).

As the Oxford Dermatology Skin Cancer Research Lead, she directs an active translational research programme in cutaneous oncology, serving as Chief Investigator on clinical and translational trials at local, national, and international levels. She has been instrumental in shaping the UK’s skin cancer clinical trials portfolio, working closely with the UK Dermatology Clinical Trials Network, and has secured nationally competitive funding from Cancer Research UK and the NIHR Health Technology Assessment programme.

Dr Matin also provides national leadership in the development and adoption of AI in dermatology. Since 2020, she has chaired the British Association of Dermatologists’ AI Working Party Group and co-leads the Dermatology AI Supra-interest Group at the Alan Turing Institute. She is Research lead for the UK AI Skin Consortium. Her research focuses on improving the quality and diversity of AI datasets in dermatology. She co-led the international STANDING Together project (datadiversity.org), addressing algorithmic bias and promoting transparency in health data. She also advises on national AI initiatives as a member of the MHRA Software/AI as a Medical Device Expert Advisory Group and the Interim Medical Devices Committee.

In addition to her research leadership, she contributes to teaching and mentorship as a faculty lecturer on the MSc in Applied Digital Health, where she supervises student dissertations on skin AI applications.

Clinically, Dr Matin leads the Oxford Transplant and Immunosuppressed Dermatology Service, as a nationally recognised expert and researcher in the field. She serves on the Executive Board of the British Society for Skin Care in Immunosuppressed Individuals, as well as the Executive Board of the UK DCTN, and also represents dermatology within the UK Translational Research Network (UK TREND).